Skip to main content
. 2020 May 2;12(5):1146. doi: 10.3390/cancers12051146

Figure 7.

Figure 7

The gene signature serves as a promising marker for therapeutic resistance. (A) NMF consensus clustering was performed to divide 1018 cell lines into two clusters. (B) IC50 values of different routine chemotherapeutic drugs and cell cycle-targeting drugs were significantly elevated in the NMF-identified CCP-high cluster. (C) Among BCa patients who received systemic chemotherapy in the training cohort, those with higher CCPRS exhibited worse CSS. (D) Among TCGA MIBC patients who received adjuvant therapies including chemo- or/and radiotherapy, those with higher CCPRS exhibited worse overall survival. (E) After initial treatment, CCPRS was progressively and significantly elevated in groups with worse outcomes (p = 0.0050).